psilocin has been researched along with Long QT Syndrome in 1 studies
psilocin: psilocybine minus the phosphate ester; RN given refers to parent cpd; structure
psilocin : A tryptamine alkaloid that is N,N-dimethyltryptamine carrying an additional hydroxy substituent at position 4. A hallucinogenic alkaloid isolated in trace amounts from Psilocybe mushrooms (also known as Teonanacatl or "magic mushrooms").
Long QT Syndrome: A condition that is characterized by episodes of fainting (SYNCOPE) and varying degree of ventricular arrhythmia as indicated by the prolonged QT interval. The inherited forms are caused by mutation of genes encoding cardiac ion channel proteins. The two major forms are ROMANO-WARD SYNDROME and JERVELL-LANGE NIELSEN SYNDROME.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dahmane, E | 1 |
| Hutson, PR | 1 |
| Gobburu, JVS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 1, Two-Part Study in Healthy Volunteers to Evaluate The Effect of Psilocybin on Cardiac Repolarization and The Effect of Food on Psilocybin Pharmacokinetics[NCT05478278] | Phase 1 | 60 participants (Actual) | Interventional | 2022-06-22 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for psilocin and Long QT Syndrome
| Article | Year |
|---|---|
Exposure-Response Analysis to Assess the Concentration-QTc Relationship of Psilocybin/Psilocin.
Topics: Adult; Dose-Response Relationship, Drug; Electrocardiography; Female; Hallucinogens; Healthy Volunte | 2021 |